Business
HCW Biologics to Showcase Two Novel Groups of Fusion Molecules Created with Proprietary and Versatile TOBI™ Platform At the 105th Annual Meeting of the American Association of Immunologists
Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells Without Using Feeder CellsSufficient for Off-the-Shelf Multi-Dose Adoptive Cell
About this update from Hcw Biologics Inc.
[{"type":"text","content":"Cytokine-Based Fusion Proteins to Activate and Expand Memory-Like NK Cells Without Using Feeder CellsSufficient for Off-the-Shelf Multi-Dose Adoptive Cell Therapy Cytokine-Based Fusion Proteins to Expand Human Regulatory T Cells That Circumvents Need for Magnetic BeadsFor Adoptive Cell Therapy for Autoimmune and Inflammatory Diseases MIRAMAR, Fla., May 05, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammaging, that is, chronic, low-grade inflammation, and age-related diseases, is presenting two groups of novel immunotherapeutics created with its proprietary and powerful Tissue factOr-Based fusIon (TOBI™) discovery platform at the 105th Annual Meeting of the American Association of Immunologists (AAI), or Immunology 2022. “HCW Biologics has invented a unique solution for providing clinical-grade fusion proteins for therapeutic use,” stated Dr. Hing Wong, Founder and CEO of HCW Biologics. “Immunology 2022 is our opportunity to showcase the power and versatility of our TOBI™ discovery platform. The first program will feature the benefits of the use of our fusion proteins without the need of feeder cells to address the challenges for supporting a multiple-dose infusion of memory-like NK cells in the clinic for cancer.” Dr. Wong continued, “Immunology 2022 also provides us with an ideal audience for the introduction to our program for the expansion of regulatory T cells (Treg cells) for the treatment of autoimmune and inflammatory diseases. The benefits of Treg cells in the treatment of inflammatory diseases are well-known, but manufacturing these therapies are labor intensive, lack consistency, and are difficult to scale. HCW Biologics has developed an approach that does not rely on magnetic beads. We also showcase our proprietary human monoclonal antibodies for generating target-specific Treg cells. We believe our unique approach could potentially open up Treg therapy as an adoptive cell therapy that could address a broad range of inflammatory pathologies.” Oral and Poster Presentation for Expansion of Memory-Like NK Cells Title:A feeder cell-free activation and expansion strategy to generate memory-like NK cells sufficient for off-the-sh...